Month: March 2023

Dundee Corporation Returns to Profit in 2022 and Announces Fourth Quarter and Year-End Results

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) — Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announced its financial results for the three months and year ended December 31, 2022. All currency amounts in this press release are in Canadian dollars except as otherwise indicated. FOURTH QUARTER AND YEAR-END 2022 RESULTSReported net income from investments for the fourth quarter of 2022 of $39.9 million (2021 – $12.1 million). For the year ended December 31, 2022, the Corporation reported net income from investments of $53.6 million (2021 – loss of $38.5 million).Reported net earnings attributable to owners of the Corporation for the fourth quarter of 2022 of $26.0 million (2021 – loss of $13.6 million), or earnings of $0.28 per share, before the effect of any dilutive securities (2021 – loss of $0.17 per share)....

Equus Announces Fourh Quarter Net Asset Value

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

HOUSTON, March 28, 2023 (GLOBE NEWSWIRE) — Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of December 31, 2022, of $35.2 million. Net asset value per share decreased to $2.61 as of December 31, 2022, from $2.68 as of September 30, 2022. Comparative data is summarized below (in thousands, except per share amounts):As of the Quarter Ended 12/31/2022 9/30/2022 6/30/2022 3/31/2022 12/31/2021Net assets $35,237 $36,230 $37,155 $37,435 $36,365Shares outstanding 13,518 13,518 13,518 13,518 13,518Net assets per share $2.61 $2.68 $2.75 $2.77 $2.69The following was the principal contributor to the increase in fair value of the Company’s portfolio holdings in 2022:Increase in the Value of Equus Energy. During 2022, the fair value of Equus Energy, LLC, increased from $13.0 million...

Nobel Withdraws From Option to Acquire the Algarrobo Copper Project in Chile

Written by Customer Service on March 28, 2023. Posted in Mergers And Acquisitions.

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX–V: NBLC; OTC: NBTRF) (the “Company” or “Nobel”) has decided to withdraw from its option to acquire the Algarrobo project (the “Project”) in Chile. According to Vern Arseneau, COO of Nobel, “After completing an extensive drill campaign on multiple target areas and reviewing the data from the Project, we have concluded that although there remains some potential for a deep porphyry on the property, alteration assemblages suggest it is likely too deep and in an area with a very thick dune cover and as such unlikely to be an economically viable target.” Qualified Person The scientific and technical information in this news release has been reviewed and approved by Mr. David Gower, P.Geo., as defined by National Instrument 43-101 of the Canadian Securities Administrators. About...

DLC Releases Annual 2022 Results; Achieves Annual Funded Volumes of $70.6 Billion

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 28, 2023 (GLOBE NEWSWIRE) — Dominion Lending Centres Inc. (TSX:DLCG) (“DLCG” or the “Corporation”) is pleased to report its financial results for the three months and year ended December 31, 2022 (“Q4-2022” and “annual”, respectively). For complete information, readers should refer to the annual audited consolidated financial statements, management discussion and analysis (“MD&A”) and annual information form (“AIF”) which are dated March 28, 2023 and available on SEDAR at www.sedar.com and on the Corporation’s website at www.dlcg.ca. All amounts are presented in Canadian dollars unless otherwise stated. Reference herein to the Dominion Lending Centres Group of Companies (the “DLC Group” or “Core Business Operations”) includes the Corporation and its three main subsidiaries, MCC Mortgage Centres...

GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

GreenLight’s RTP greenhouse facility in North Carolina GreenLight’s RTP greenhouse facility in North CarolinaTwo agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect honeybees from Varroa miteUpdated clinical strategy to accelerate development of its next-generation Covid vaccine candidate; decision to advance universal pan-sarbecovirus vaccine candidate Presented promising preclinical immune response data for Shingles vaccine candidate, first program in partnership with Serum Institute of India Private LimitedBOSTON, March 28, 2023 (GLOBE NEWSWIRE) — GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest...

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

LONDON, March 28, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights. “In 2022, we made important progress in the ongoing advancement of our core rare disease programs. The data from our Phase 2 ASTRAEUS study of alvelestat in severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) were highly encouraging, and formed the basis for productive discussions with the regulatory agencies in both the U.S. and EU, culminating in our recent announcement of the details of our potential pivotal study design,” said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. “We believe our...

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

– Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with anti-PD-1 and beyond – – Roche sponsoring randomized, multi-national phase 1b/2 trial of novel triple combination therapy in first-line liver cancer, leveraging safety profile of masked, anti-CTLA-4 SAFEbody® ADG126 – – Sanofi and Exelixis collaborations present multi-billion dollar opportunity for non-dilutive funding via milestones and royalties – – Cash balance of US$143.8 million supports streamlined operations into 2025 – SAN DIEGO and SUZHOU, China, March 28, 2023 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company...

Healthcare Triangle Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

30% annual revenue growth to $46 million led by software services and successful integration of Devcool acquisition PLEASANTON, Calif., March 28, 2023 (GLOBE NEWSWIRE) — Healthcare Triangle, Inc. (Nasdaq: HCTI), a leading provider of cloud and digital transformation, managed services, and data analytics solutions for the healthcare and life sciences industry, today announced financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial ResultsRevenue: Total revenue was $11.3 million, representing growth of 23% compared to the fourth quarter of 2021. Revenue from the Software Services and Platform Services segments increased by 82% and 55%, respectively, partially offset by a 31% decrease in Managed Services and Support.GAAP loss from operations: GAAP loss from operations was $4.9...

Ekso Bionics Reports Fourth Quarter and Year End 2022 Results

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

SAN RAFAEL, Calif., March 28, 2023 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2022. Recent Highlights and AccomplishmentsCompleted the acquisition of the Human Motion Control (“HMC”) business unit including the Indego® product line from Parker Hannifin Corporation Generated revenue of $12.9 million for the 2022 full year, an increase of 15% year-over-year Booked a total of 100 EksoHealth devices for the 2022 full year, including Indego bookings post-acquisition Strong cash position of $20.5 million as of December 31, 2022“With the successful acquisition of the Indego product line, FDA clearance of EksoNR for rehabilitation use in...

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Written by Customer Service on March 28, 2023. Posted in Earnings Releases And Operating Results.

MIRAMAR, Fla., March 28, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter ended December 31, 2022. Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, stated, “We had a productive year in 2022, and our cancer program met or exceeded key milestones. In the fall, a preliminary first-in-human clinical data readout was presented at the SITC annual conference by Dr. Melissa Geller, the principal investigator for the University of Minnesota (“UMN”) sponsored Phase 1 clinical trial to evaluate...

Month: March 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals